Clobazam (Onfi) Can Cause Serious Skin Reactions, FDA Warns
The antiseizure drug clobazam (Onfi, Lundbeck) can trigger rare but potentially fatal skin reactions, the US Food and Drug Administration (FDA) announced today.
For clobazam, the skin reactions to watch for are Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients taking clobazam can experience these disorders at any time, but the risk goes up during the first 8 weeks of treatment or when treatment resumes after it was stopped. All the cases of these 2 adverse events identified by the FDA landed patients in the hospital, with 1 patient going blind and another dying.
Post a Comment